| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Autoimmune gastrointestinal dysmotility (AGID) is a clinical and limited manifestation of autoimmune dysautonomia typically associated with syncope, neuropathy, and sweating problems, but may also involve chronic gastrointestinal dysmotility.
Autoimmune GI dysmotility Test menu
Identifying gastrointestinal dysmotility as autoimmune-mediated is extremely important because patients treated with immunotherapy can see a dramatic improvement — going from persistent nausea, vomiting, and weight loss to feeling normal within a few weeks. Our algorithmic approach to AGID testing uses multiple methodologies to identify antibodies associated with the illness. Test results can direct a search for an underlying cancer and guide treatment selection.
Key testing
Advantages
Highlights
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.
Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.